536748-46-6|Eribaxaban|(2R,4R)-N1-(4-Chlorophenyl)-N2-(2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4-methoxypyrrolidine-1,2-dicarboxamide|-范德生物科技公司

Eribaxaban

NMR下载 COA and HPLC MSDS下载
names：
(2R,4R)-N1-(4-Chlorophenyl)-N2-(2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4-methoxypyrrolidine-1,2-dicarboxamide
CAS号：
536748-46-6
MDL Number：
MF(分子式)： C24H22ClFN4O4 MW(分子量)： 484.9124
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Eribaxaban
英文别名	PD348292; PD-348292; PD 348292; PD0348292; PD-0348292; PD 0348292; PD348,292; PD-348,292; PD 348,292; Eribaxaban
CAS号	536748-46-6
Inchi	InChI=1S/C24H22ClFN4O4/c1-34-18-13-21(30(14-18)24(33)27-16-7-5-15(25)6-8-16)23(32)28-20-10-9-17(12-19(20)26)29-11-3-2-4-22(29)31/h2-12,18,21H,13-14H2,1H3,(H,27,33)(H,28,32)/t18-,21-/m1/s1
InchiKey	QQBKAVAGLMGMHI-WIYYLYMNSA-N
分子式 Formula	C24H22ClFN4O4
分子量 Molecular Weight	484.9124
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Eribaxaban(CAS:536748-46-6):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Eribaxaban, also known as PD348292 or PD0348292, is an oral factor Xa inhibitor under development for the treatment and prevention of thrombotic disorders. PD0348292 inhibited arterial thrombosis comparable to aspirin plus clopidogrel. Perfusion chamber methodology may be useful in predicting in-vivo antithrombotic efficacy.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Cohen AT, Boyd RA, Mandema JW, Dicarlo L, Pak R; A5571010 Investigators. An adaptive-design dose-ranging study of PD 0348292, an oral factor Xa inhibitor, for thromboprophylaxis after total knee replacement surgery. J Thromb Haemost. 2013 Aug;11(8):1503-10. doi: 10.1111/jth.12328. PubMed PMID: 23782955.

[2]Perzborn E. Factor Xa inhibitors--new anticoagulants for secondary haemostasis. Hamostaseologie. 2009 Aug;29(3):260-7. PubMed PMID: 19644596.

[3] Gómez-Outes A, Lecumberri R, Pozo C, Rocha E. New anticoagulants: focus on venous thromboembolism. Curr Vasc Pharmacol. 2009 Jul;7(3):309-29. Review. PubMed PMID: 19601856.

[4] Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet. 2009;48(1):1-22. doi: 10.2165/0003088-200948010-00001. Review. PubMed PMID: 19071881.

[5] Karnicki K, Leadley RJ Jr, Baxi S, Peterson T, Wysokinski W, McBane RD 2nd. Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis. Thromb Haemost. 2008 Apr;99(4):759-66. doi: 10.1160/TH07-09-0576. PubMed PMID: 18392334.

6: Andreotti F, Santucci E. Expanding the role of coagulation in arterial thrombosis: evidence from animal models using a new factor Xa inhibitor. Thromb Haemost. 2008 Apr;99(4):651-2. doi: 10.1160/TH08-02-0112. PubMed PMID: 18392319.7: McBane RD 2nd, Leadley RJ Jr, Baxi SM, Karnicki K, Wysokinski W. Iliac venous stenting: antithrombotic efficacy of PD0348292, an oral direct Factor Xa inhibitor, compared with antiplatelet agents in pigs. Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):413-8. Epub 2007 Dec 20. PubMed PMID: 18096830.8: Kohrt JT, Bigge CF, Bryant JW, Casimiro-Garcia A, Chi L, Cody WL, Dahring T, Dudley DA, Filipski KJ, Haarer S, Heemstra R, Janiczek N, Narasimhan L, McClanahan T, Peterson JT, Sahasrabudhe V, Schaum R, Van Huis CA, Welch KM, Zhang E, Leadley RJ, Edmunds JJ. The discovery of (2R,4R)-N-(4-chlorophenyl)-N- (2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4-methoxypyrrolidine-1,2-dicarboxamide (PD 0348292), an orally efficacious factor Xa inhibitor. Chem Biol Drug Des. 2007 Aug;70(2):100-12. PubMed PMID: 17683371.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开